October 8, 2026 – San Diego, California
Dr. Qinhua Cindy Ru, Managing Director of CRC Oncology, will join a panel discussion on China’s biopharmaceutical innovation and cross-border partnering at today’s San Diego CEO Summit.
The discussion will explore opportunities for U.S. companies to work with Chinese biotechnology and pharmaceutical organizations, including licensing and co-development of China-originated assets, the role of investigator-initiated trials (IITs), and considerations for developing clinical data for use across markets.
“China-originated assets can create meaningful opportunities for companies seeking to advance innovative therapies,” said Dr. Ru. “The key is to assess each program on its evidence, development needs, and operational foundation—and to consider the intended global pathway from the beginning.”
Dr. Ru founded CRC Oncology in San Diego in 2018. The company supports biotechnology organizations with regulatory, clinical development, competitive landscape, business development, and GxP quality services for oncology and other therapies addressing unmet medical needs.
The China panel will also feature Echo Hindle-Yang, President and CEO of MSQ Ventures, and Alan Kholos, Chief Administrative Officer of HUYABIO International. The panel is scheduled for October 8, 2026, as part of the San Diego CEO Summit.
About CRC Oncology
CRC Oncology is a San Diego-based biotechnology consulting company founded in 2018. It supports companies developing therapies for unmet medical needs through regulatory strategy, clinical development, competitive landscape, and business development support, and GxP quality and diligence services.
Media Contact:
Rachel Bennett
Media Communications
CRC Oncology Corp
rbennett@crconc.org